Replies to post #14515 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

I wish I could read that fast. I caught a glimpse of something when blurred out it looked like Pfizer Inc. as a sponsor. So I thought I would clear my history and cache and tried it again, but this time I took a video as I was opening the page. It worked.

[Just the facts maam]

Silvr, I would not be surprised if ANIP/Novitium got the rights to Nuray Chemicals IP related to Tafamidis, and have entered into a collaborative agreement with Pfizer to develop a replacement for a new and improved version of their Vyndamax® (Tafamidis), and Vyndaqel® (tafamidis meglumine) which starts to lose some patents and exclusivity December 2023 through 2024. This will allow Pfizer to switch their patients to the new drug which patent coverage extends to 2041.

Nuray Patent

Samy is the lead inventor for the patent.

Vyndaquel IP expiration

Vyndamax IP expration

FYI, Vyndaquel and Vyndamax accounted for $782 million in revenue for Pfizer in Q2.

JMHO